Image

The Gut Microbiome and Serum Metabolites as a Biological Mechanism Underlying Pain in Kidney Transplantation

The Gut Microbiome and Serum Metabolites as a Biological Mechanism Underlying Pain in Kidney Transplantation

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Study Summary Nearly half (47%) of people with end-stage kidney disease (ESKD) whose kidney function is restored after kidney transplantation experience chronic pain compared to 19% of adults in the US general population. Pain is associated with comorbid fatigue, depression and anxiety, and withdrawal from usual physical and social activities; resulting in an inability to participate in and enjoy life. Severe pain can result in nonadherence to immunosuppression and treatment protocols and result in an increased risk of rejection, graft loss, and mortality. The role of symbiotic microbes (microbiota) in the gastrointestinal tract, and their functional genes (microbiome), is well established in diseases involving pain. Diet and stress play a major role in synthesis of signaling molecules critical to immunologic, metabolic, and endocrine pathways regulating chronic pain. Dietary patterns change dramatically after transplantation, as recipients move from a restricted "renal" diet to a regular diet, often resulting in increased consumption of foods high in sugars and fat. Moreover, psychological stress significantly impairs the function of the microbiome, initiating biological pathways involved in pain, leading to a disproportionate pain burden. Because the microbiome, serum metabolites, and pain are dynamic, our novel investigation will employ a prospective repeated measures design to interrogate the dynamic temporal relationships between the microbiome, metabolites associated with pathways regulating pain, transplantation factors (e.g. immunosuppression, kidney function), changing dietary patterns, and perceived stress, on pain scores before and after kidney transplantation. We posit the gut microbiome, and its byproducts, may partially explain the underlying biological mechanisms of pain Interference in kidney disease. We will address three aims: 1) To determine differential dynamic temporal relationships between microbial composition/functional genes and circulating serum metabolites in KTRs with pain vs no pain, 2) To determine the moderation effects of diet and perceived stress on dynamic temporal relationships between microbiome features, serum metabolites, and pain scores among KTRs, and 3) To use machine learning algorithms to identify host-microbial interactions that are causally linked to pain interference among KTRs. Because kidney function is restored, the kidney transplant model is powerful to study the longitudinal relationships between the microbiome, circulating metabolites and chronic pain in people with ESKD to develop patient-centered interventions to treat pain across the spectrum of CKD.

Description

Objectives Aim 1: To determine differential dynamic temporal relationships between microbial composition/ functional genes and circulating serum metabolites in KTRs with pain vs no pain. H1: Specific gut microbiota phenotypes (e.g., low abundance of Akkermansia, differential beta diversity indices) will be identified in those with pain vs no pain, and microbiota taxa will be associated with serum metabolite levels (e.g., decreased SCFAs, serotonin, kynurenic acid, indoles; increased neurotoxic quinolinic acid, endotoxin, urea).

Aim 2: To determine the moderation effects of diet and stress on dynamic temporal relationships between microbiome features, serum metabolites, and pain scores among KTRs. H2: Those with pain will report higher stress and consume a low fiber diet (e.g., fiber grams per 1000 kcal), resulting in a shift to a proinflammation microbiome phenotype (e.g., lower alpha diversity, lower abundances of Akkermansia, higher Enterococcus), lower serum levels of SCFAs, and higher levels of neurotoxic metabolites (e.g., quinolinic acid).

Aim 3 (exploratory): To identify host-microbial interactions that are causally linked to PI among KTRs. H3: Integration of longitudinal data from biomarkers associated with PI into clinical-based dynamic machine learning models (e.g., race, age, income, kidney function, diet, stress) will improve their accuracy by >30% as host and microbial biomarkers can better capture environmental factors associated with PI.

Eligibility

Inclusion Criteria:

        Participants must: (1) be receiving a kidney transplant at the University of Illinois
        Hospital & Health Sciences System (UI Health) Transplant Center at the University of
        Illinois Chicago (UIC), (2) be 18 years of age or older (adult), and (3) understand the
        study process and provide written informed consent to participate.
        Exclusion Criteria:
        (1) taking corticosteroids with prednisone at a dose of >30 mg/day or other forms of
        corticosteroid at the equivalent dose (e.g., for systemic lupus erythematosus or rheumatoid
        arthritis), (2) having taken systemic antimicrobials (except prophylactic penicillin) in
        the preceding 4 weeks, (3) having received a previous solid organ transplant, (4) history
        of colon cancer or of an inflammatory bowel disease, (5) planning to receive a multiorgan
        transplant (e.g., simultaneous pancreas and kidney transplant), (6) having a history of
        Clostridium difficile infection in the preceding 8 weeks.

Study details
    Kidney Transplant Symptoms
    Gut Microbiome

NCT06206486

University of Illinois at Chicago

26 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.